Gubra surges on AbbVie partnership for obesity treatment

Gubra A/S

03/03/2025 08:45

** Shares in Gubra GUBRA.CO surge 29% at market open after the Danish biotech company signed a licensing deal with AbbVie ABBV.N to develop an amylin analog for obesity treatment

** The partnership marks AbbVie's entrance into the obesity field, the companies say in a press release

** Terms of the deal include $305 million as an upfront payment to Gubra and $1.875 billion in potential milestones, they add

** Analysts at Van Lanschot Kempen view the terms as "attractive", saying they appear to be higher than the broker's valuation

** Kempen adds AbbVie is a good partner for Gubra, as it can accelerate mid- and late-stage development of the GUBamy amylin analog programme, while offering infrastructure for a commercial launch

** Gubra's shares were up 19% by 0824 GMT, on track for their best day ever

 (Reporting by Vera Dvorakova)

 ((vera.dvorakova@thomsonreuters.com))